Riesgo de cáncer gástrico en pacientes con gastritis atrófica y metaplasia intestinal en estadios OLGA y OLGIM III y IV: revisión sistemática y metanálisis

Vista sencilla de ítem
dc.contributor.advisorOtero Regino, William Albertospa
dc.contributor.authorFrias Ordoñez, Juan Sebastianspa
dc.contributor.cvlachttps://scienti.minciencias.gov.co/cvlac/visualizador/generarCurriculoCv.do?cod_rh=0001772314spa
dc.contributor.googlescholarhttps://scholar.google.com/citations?user=fV--MAwAAAAJ&hl=es&oi=aospa
dc.contributor.orcidFrias Ordoñez, Juan Sebastian [0000000327352922]spa
dc.contributor.researchgatehttps://www.researchgate.net/profile/Juan-Frias-Ordonezspa
dc.contributor.scopusFrias Ordoñez, Juan Sebastian [57193738162]spa
dc.date.accessioned2024-12-11T13:41:54Z
dc.date.available2024-12-11T13:41:54Z
dc.date.issued2024
dc.descriptionilustraciones, diagramasspa
dc.description.abstractIntroducción y objetivo: Estudios recientes han encontrado que pacientes con OLGA II, también pueden tener riesgo de cáncer gástrico (CG) a largo plazo y más aún si tienen familiares de primer grado con CG. El objetivo del presente metaanálisis es determinar si los estadios de OLGA II-IV tienen riesgo de CG y cuál es su magnitud, así como también estimar si el riesgo aumenta cuando hay familiares de primer grado con CG. Metodología: Revisión sistemática y metaanálisis. Se buscarán en varias bases de datos, incluyendo PubMed, EMBASE, Medline y la biblioteca Cochrane, artículos publicados en los últimos 10 años hasta mayo de 2024 sobre la asociación entre los diferentes estadios OLGA/OLGIM y el riesgo de GC. Análisis estadístico con estimación del efecto en términos de Odds Ratio (OR), riesgo relativo (RR) e intervalo de confianza del 95%. La heterogeneidad se estimará con I2 y Chi2. Resultados: De 273 artículos recuperados mediante nuestra búsqueda bibliográfica, se incluyeron un total 28 estudios que comprendían 23390 pacientes, se incluyeron 15 estudios de casos y controles, corte transversal, y 13 estudios de cohortes. El metaanálisis demostró una asociación significativa entre los estadios II-IV de OLGA/OLGIM y cáncer gástrico. El análisis de subgrupos en poblaciones con baja prevalencia de infección por H. pylori no encontró asociación del puntaje OLGIM en los estudios de cohorte. Conclusiones: Se presenta una versión resumida de las asociaciones estimadas de los diferentes estadios de OLGA/OLGIM y riesgo de CG (Texto tomado de la fuente).spa
dc.description.abstractIntroduction and objective: Recent studies have found that patients with OLGA II may also be at risk of gastric cancer (GC) in the long term and even more so if they have first-degree relatives with GC. The aim of the present meta-analysis is to determine whether OLGA stages II-IV are at risk of GC and what is its magnitude, as well as to estimate whether the risk increases when there are first-degree relatives with GC. Methodology: Systematic review and meta-analysis. Several databases, including PubMed, EMBASE, Medline and Cochrane library, will be searched for articles published in the last 10 years until May 2024 on the association between different OLGA/OLGIM stages and GC risk. Statistical analysis with estimation of effect in terms of Odds Ratio (OR), relative risk (RR) and 95% confidence interval. Heterogeneity will be estimated with I2 and Chi2. Results: Of 273 articles retrieved through our literature search, a total of 28 studies comprising 23390 patients were included, 15 case-control, cross-sectional, and 13 cohort studies. The meta-analysis demonstrated a significant association between OLGA/OLGIM stages II-IV and gastric cancer. Subgroup analysis in populations with low prevalence of H. pylori infection found no association of OLGIM score in cohort studies. Conclusions: A summarized version of the estimated associations of different OLGA/OLGIM stages and GC risk is presented.eng
dc.description.degreelevelEspecialidades Médicasspa
dc.description.degreenameEspecialista en Gastroenterologíaspa
dc.description.methodsRevisión sistemática y metaanálisis. Se buscarán en varias bases de datos, incluyendo PubMed, EMBASE, Medline y la biblioteca Cochrane, artículos publicados en los últimos 10 años hasta mayo de 2024 sobre la asociación entre los diferentes estadios OLGA/OLGIM y el riesgo de GC. Análisis estadístico con estimación del efecto en términos de Odds Ratio (OR), riesgo relativo (RR) e intervalo de confianza del 95%. La heterogeneidad se estimará con I2 y Chi2.spa
dc.description.researchareaCáncer gástricospa
dc.format.extent59 páginas + anexosspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.instnameUniversidad Nacional de Colombiaspa
dc.identifier.reponameRepositorio Institucional Universidad Nacional de Colombiaspa
dc.identifier.repourlhttps://repositorio.unal.edu.co/spa
dc.identifier.urihttps://repositorio.unal.edu.co/handle/unal/87287
dc.language.isospaspa
dc.publisherUniversidad Nacional de Colombiaspa
dc.publisher.branchUniversidad Nacional de Colombia - Sede Bogotáspa
dc.publisher.facultyFacultad de Medicinaspa
dc.publisher.placeBogotá, Colombiaspa
dc.publisher.programBogotá - Medicina - Especialidad en Gastroenterologíaspa
dc.relation.references2. P C. Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res [Internet]. 1992;52(24):6735–40. Available from: https://pubmed.ncbi.nlm.nih.gov/1458460/spa
dc.relation.references3. Lahner E, Bordi C, Cattaruzza MS, Iannoni C, Milione M, Delle Fave G, et al. Long-term follow-up in atrophic body gastritis patients: Atrophy and intestinal metaplasia are persistent lesions irrespective of Helicobacter pylori infection. Aliment Pharmacol Ther. 2005;22(5):471–81.spa
dc.relation.references4. De Vries AC, Haringsma J, Kuipers EJ. The detection, surveillance and treatment of premalignant gastric lesions related to Helicobacter pylori infection. Helicobacter. 2007;12(1):1–15.spa
dc.relation.references5. Filipe MI, Muñoz N, Matko I, Kato I, Pompe‐Kirn V, Jutersek A, et al. Intestinal metaplasia types and the risk of gastric cancer: A cohort study in Slovenia. Int J Cancer. 1994;57(3):324–9.spa
dc.relation.references6. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001 Sep 13;345(11):784-9. doi: 10.1056/NEJMoa001999.spa
dc.relation.references7. Rokkas T, Filipe MI, Sladen GE. Detection of an increased incidence of early gastric cancer in patients with intestinal metaplasia type III who are closely followed up. Gut. 1991;32(10):1110–3.spa
dc.relation.references8. Engevik AC, Kaji I, Goldenring JR. The physiology of the gastric parietal cell. Physiol Rev. 2020;100(2):573–602.spa
dc.relation.references9. Rugge M, De Boni M, Pennelli G, De Bona M, Giacomelli L, Fassan M, et al. Gastritis OLGA-staging and gastric cancer risk: A twelve-year clinico-pathological follow-up study. Aliment Pharmacol Ther. 2010;31(10):1104–11.spa
dc.relation.references10. Park YH, Kim N. Review of Atrophic Gastritis and Intestinal Metaplasia as a Premalignant Lesion of Gastric Cancer. J Cancer Prev. 2015;20(1):25–40.spa
dc.relation.references11. Cho SJ, Choi IJ, Kook MC, Nam BH, Kim CG, Lee JY, et al. Staging of intestinal- and diffuse-type gastric cancers with the OLGA and OLGIM staging systems. Aliment Pharmacol Ther. 2013;38(10):1292–302.spa
dc.relation.references12. Capelle LG, de Vries AC, Haringsma J, Ter Borg F, de Vries RA, Bruno MJ, et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc. 2010;71(7):1150–8.spa
dc.relation.references13. Rugge M, Correa P, Di Mario F, El-Omar E, Fiocca R, Geboes K, et al. OLGA staging for gastritis: A tutorial. Dig Liver Dis. 2008;40(8):650–8.spa
dc.relation.references14. Dinis-Ribeiro M, Areia M, De Vries AC, Marcos-Pinto R, Monteiro-Soares M, Oconnor A, et al. Management of precancerous conditions and lesions in the stomach (MAPS): Guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa . Endoscopy. 2012;44(1):74–94.spa
dc.relation.references15. De Re V, Orzes E, Canzonieri V, Maiero S, Fornasarig M, Alessandrini L, et al. Pepsinogens to distinguish patients with gastric intestinal metaplasia and helicobacter pylori infection among populations at risk for gastric cancer. Clin Transl Gastroenterol. 2016;7(7):1–2.spa
dc.relation.references16. Yue H, Shan L, Bin L. The significance of OLGA and OLGIM staging systems in the risk assessment of gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2018;21(4):579–87.spa
dc.relation.references17. Molaei M, Ehtiati A, Mashayekhi R, Rafizadeh M, Zojaji H, Mirsattari D, et al. Gastric atrophy: Use of OLGA staging system in practice. Gastroenterol Hepatol from Bed to Bench. 2016;9(1):25–9.spa
dc.relation.references18. Correa P, Piazuelo MB, Wilson KT. Pathology of gastric intestinal metaplasia: Clinical implications. Am J Gastroenterol. 2010;105(3):493–8.spa
dc.relation.references19. Gastric cancer . National Cancer Institute (consultado el 15/05/2024 en: https://www.cancer.gov/types/stomach.spa
dc.relation.references20. Murakami T. Pathomorphological diagnosis: definition and gross classification of early gastric cancer. Gann Monogr Cancer Res. 1971;11:53-55.spa
dc.relation.references21. Morson BC, Sobin LH, Grundmann E, Johansen A, Nagayo T, Serck-Hanssen A. Precancerous conditions and epithelial dysplasia in the stomach. J Clin Pathol. 1980;33(8):711–21.spa
dc.relation.references22. WHO Classification of tumors. Digestive system tumors. Tumors of the stomach. WHO Classification of Tumors Editorial Board. 5th Ed. Lyon: IARC press; 2019, pp. 59-110.spa
dc.relation.references23. Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: Descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014;23(5):700–13.spa
dc.relation.references24. Marques-Silva L, Areia M, Elvas L, Dinis-Ribeiro M. Prevalence of gastric precancerous conditions: A systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2014;26(4):378–87.spa
dc.relation.references25. Liang B, Yuan Y, Peng XJ, Liu XL, Hu XK, Xing DM. Current and future perspectives for Helicobacter pylori treatment and management: From antibiotics to probiotics. Front Cell Infect Microbiol. 2022;12:20–1.spa
dc.relation.references26. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health. Obes Res. 1998;6 Suppl 2:9813653.spa
dc.relation.references27. WHO global report on trends in prevalence of tobacco use 2000-2025, fourth edition. WHO, Geneva, 2021.spa
dc.relation.references28. Mccarron DA, Kazaks AG, Geerling JC, Stern JS, Graudal NA. Normal range of human dietary sodium intake: A perspective based on 24-hour urinary sodium excretion worldwide. Am J Hypertens. 2013;26(10):1218–23.spa
dc.relation.references29. Beard JC, Swager TM. An Organic Chemist’s Guide to N-Nitrosamines: Their Structure, Reactivity, and Role as Contaminants. J Org Chem. 2021;86(3):2037–57.spa
dc.relation.references30. Naeher LP, Brauer M, Lipsett M, Zelikoff JT, Simpson CD, Koenig JQ, et al. Woodsmoke health effects: A review. Inhal Toxicol. 2007;19(1):67–106.spa
dc.relation.references31. Wu GA, Terol J, Ibanez V, López-García A, Pérez-Román E, Borredá C, et al. Genomics of the origin and evolution of Citrus. Nature. 2018;554(7692):311–6.spa
dc.relation.references32. Stanaway JD, Afshin A, Ashbaugh C, Bisignano C, Brauer M, Ferrara G, et al. Health effects associated with vegetable consumption: a Burden of Proof study. Nat Med. 2022;28(10):2066–74.spa
dc.relation.references33. Alcohol’s Effects on Health.National Institute on Alcohol Abuse and Alcoholism. (Consultado el 15/05/2024 en: https://www.niaaa.nih.gov/alcohol-health/overview-alcohol-consumption/moderate-binge-drinking).spa
dc.relation.references34. Laporte RE, Montoye HJ, Caspersen CJ. Physical Activity, Exercise, and Physical Fitness: Definitions and Distinctions for Health-Related Research Synopsis. Public Health Rep. 1985;100(2):126–31.spa
dc.relation.references35. Peavitt, Helen (15 November 2017). Refrigerator: The Story of Cool in the Kitchen. Reaktion Books. p. 8. ISBN 978-1-78023-797-8.spa
dc.relation.references36. Liu Q, Ding L, Qiu X, Meng F. Updated evaluation of endoscopic submucosal dissection versus surgery for early gastric cancer: A systematic review and meta-analysis. Int J Surg. 2020;73:28–41.spa
dc.relation.references37. Ho SWT, Tan P. Dissection of gastric cancer heterogeneity for precision oncology. Cancer Sci. 2019;110(11):3405–14.spa
dc.relation.references38. Koulis A, Buckle A, Boussioutas A. Premalignant lesions and gastric cancer: Current understanding. World J Gastrointest Oncol. 2019;11(9):665–78.spa
dc.relation.references39. Bonelli P, Borrelli A, Tuccillo FM, Silvestro L, Palaia R, Buonaguro FM. Precision medicine in gastric cancer. World J Gastrointest Oncol. 2019;11(10):804–29.spa
dc.relation.references40. Asaka M, Mabe K. Strategies for eliminating death from gastric cancer in Japan. Proc Japan Acad Ser B Phys Biol Sci. 2014;90(7):251–8.spa
dc.relation.references41. Wang X, Zhao J, Shen Z, Fairweather M, Enzinger PC, Sun Y, et al. Multidisciplinary Approach in Improving Survival Outcome of Early-Stage Gastric Cancer. J Surg Res. 2020;255:285–96.spa
dc.relation.references42. Mickevicius A, Ignatavicius P, Markelis R, Parseliunas A, Butkute D, Kiudelis M, et al. Trends and results in treatment of gastric cancer over last two decades at single East European centre: A cohort study. BMC Surg. 2014;14(1):1–2.spa
dc.relation.references43. Oh SE, An JY, Choi MG, Sohn TS, Bae JM, Kim S, et al. Long term oncological outcome of patients with grossly early gastric cancer-mimicking advanced gastric cancer. Eur J Surg Oncol. 2020;46(7):1262–8.spa
dc.relation.references44. Estimated number of new cases in 2020, world, both sexes, all ages [Internet]. International Agency for Research/World Health Organization (IARC/WHO); 2021 [consultado el 15 de mayo de 2024]. Disponible en: https://gco.iarc.fr/today/online-analysis-pie?v=.spa
dc.relation.references45. Bae JM, Kim EH. Epstein-Barr virus and gastric cancer risk: A metaanalysis with meta-regression of case-control studies. J Prev Med Public Heal. 2016;49(2):97–107.spa
dc.relation.references46. Wroblewski LE, Peek RM, Wilson KT. Helicobacter pylori and gastric cancer: Factors that modulate disease risk. Clin Microbiol Rev. 2010;23(4):713–39.spa
dc.relation.references47. Cats A, Meuwissen SGM, Forman D, Craanen ME, Kuipers EJ. Helicobacter pylori: A true carcinogen? Eur J Gastroenterol Hepatol. 1998;10(6):447–50.spa
dc.relation.references48. Conteduca V, Sansonno D, Lauletta G, Russi S, Ingravallo G, Dammacco F. H. pylori infection and gastric cancer: State of the art (Review). Int J Oncol. 2013;42(1):5–18.spa
dc.relation.references49. Rick JR, Goldman M, Semino-Mora C, Liu H, Olsen C, Rueda-Pedraza E, et al. In situ expression of cagA and risk of gastroduodenal disease in helicobacter pylori-infected children. J Pediatr Gastroenterol Nutr. 2010;50(2):167–72.spa
dc.relation.references50. Hatakeyama M. Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat Rev Cancer. 2004;4(9):688–94.spa
dc.relation.references51. Iizasa H, Nanbo A, Nishikawa J, Jinushi M, Yoshiyama H. Epstein-barr virus (EBV)-associated gastric carcinoma. Viruses. 2012;4(12):3420–39.spa
dc.relation.references52. Kim YS, Paik SR, Kim HK, Yeom BW, Kim I, Lee D. Epstein-Barr virus and CD21 expression in gastrointestinal tumors. Pathol Res Pract. 1998;194(10):705–11.spa
dc.relation.references53. Kim J, Cho YA, Choi WJ, Jeong SH. Gene-diet interactions in gastric cancer risk: A systematic review. World J Gastroenterol. 2014;20(28):9600–10.spa
dc.relation.references54. Zhang Z, Zhang X. Salt taste preference, sodium intake and gastric cancer in China. Asian Pacific J Cancer Prev. 2011;12(5):1207–10.spa
dc.relation.references55. Keszei AP, Goldbohm RA, Schouten LJ, Jakszyn P, Van Den Brandt PA. Dietary N-nitroso compounds, endogenous nitrosation, and the risk of esophageal and gastric cancer subtypes in the Netherlands Cohort Study. Am J Clin Nutr. 2013;97(1):135–46.spa
dc.relation.references56. Moy KA, Fan Y, Wang R, Gao YT, Yu MC, Yuan JM. Alcohol and tobacco use in relation to gastric cancer: A prospective study of men in Shanghai, China. Cancer Epidemiol Biomarkers Prev. 2010;19(9):2287–97.spa
dc.relation.references57. Duell EJ, Travier N, Lujan-Barroso L, Clavel-Chapelon F, Boutron-Ruault MC, Morois S, et al. Alcohol consumption and gastric cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Am J Clin Nutr. 2011;94(5):1266–75.spa
dc.relation.references58. Vogelaar IP, van der Post RS, Bisseling TM, van Krieken JHJM, Ligtenberg MJL, Hoogerbrugge N. Familial gastric cancer: Detection of a hereditary cause helps to understand its etiology. Hered Cancer Clin Pract. 2012;10(1):1–2.spa
dc.relation.references59. Pinheiro H, Oliveira C, Seruca R, Carneiro F. Hereditary diffuse gastric cancer - Pathophysiology and clinical management. Best Pract Res Clin Gastroenterol. 2014;28(6):1055–68.spa
dc.relation.references60. Lim SH, Kwon JW, Kim N, Kim GH, Kang JM, Park MJ, et al. Prevalence and risk factors of Helicobacter pylori infection in Korea: Nationwide multicenter study over 13 years. BMC Gastroenterol. 2013;13(1):1–2.spa
dc.relation.references61. Corso G, Marrelli D. Frequency of familial gastric cancer. Spotlight Fam Hered Gastric Cancer. 2013;11–8.spa
dc.relation.references62. Kahrilas PJ, Kishk SM, Helm JF, Dodds WJ, Harig JM, Hogan WJ. Comparison of pseudoachalasia and achalasia. Am J Med. 1987;82(3):439–46.spa
dc.relation.references63. Wanebo HJ, Kennedy BJ, Chmiel J, Steele G, Winchester D, Osteen R. Cancer of the stomach A patient care study by the American college of surgeons. Ann Surg. 1993;218(5):583–92.spa
dc.relation.references64. Sawyers JL. Gastric carcinoma. Curr Probl Surg. 1995;32(2):7776992.spa
dc.relation.references65. Zagari RM, Rabitti S, Greenwood DC, Eusebi LH, Vestito A, Bazzoli F. Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis. Aliment Pharmacol Ther. 2017;46(7):657–67.spa
dc.relation.references66. Hwang YJ, Kim N, Lee HS, Lee JB, Choi YJ, Yoon H, et al. Reversibility of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication - a prospective study for up to 10 years. Aliment Pharmacol Ther. 2018;47(3):380–90.spa
dc.relation.references67. Zhao Z, Yin Z, Wang S, Wang J, Bai B, Qiu Z, et al. Meta-analysis: The diagnostic efficacy of chromoendoscopy for early gastric cancer and premalignant gastric lesions. J Gastroenterol Hepatol. 2016;31(9):1539–45.spa
dc.relation.references68. Anagnostopoulos GK, Yao K, Kaye P, Fogden E, Fortun P, Shonde A, et al. High-resolution magnification endoscopy can reliably identify normal gastric mucosa, Helicobacter pylori-associated gastritis, and gastric atrophy. Endoscopy. 2007;39(3):202–7.spa
dc.relation.references69. Ang TL, Pittayanon R, Lau JYW, Rerknimitr R, Ho SH, Singh R, et al. A multicenter randomized comparison between high-definition white light endoscopy and narrow band imaging for detection of gastric lesions. Eur J Gastroenterol Hepatol. 2015;27(12):1473–8.spa
dc.relation.references70. Ezoe Y, Muto M, Uedo N, Doyama H, Yao K, Oda I, et al. Magnifying narrowband imaging is more accurate than conventional white-light imaging in diagnosis of gastric mucosal cancer. Gastroenterology. 2011;141(6):4–5.spa
dc.relation.references71. Isajevs S, Liepniece-Karele I, Janciauskas D, Moisejevs G, Funka K, Kikuste I, et al. The effect of incisura angularis biopsy sampling on the assessment of gastritis stage. Eur J Gastroenterol Hepatol. 2014;26(5):510–3.spa
dc.relation.references72. Varbanova M, Wex T, Jechorek D, Röhl FW, Langner C, Selgrad M, et al. Impact of the angulus biopsy for the detection of gastric preneoplastic conditions and gastric cancer risk assessment. J Clin Pathol. 2016;69(1):19–25.spa
dc.relation.references73. Evans JA, Chandrasekhara V, Chathadi K V., Decker GA, Early DS, Fisher DA, et al. The role of endoscopy in the management of premalignant and malignant conditions of the stomach. Gastrointest Endosc. 2015;82(1):1–8.spa
dc.relation.references74. Matysiak-Budnik T, Camargo MC, Piazuelo MB, Leja M. Recent Guidelines on the Management of Patients with Gastric Atrophy: Common Points and Controversies. Dig Dis Sci. 2020;65(7):1899–903.spa
dc.relation.references75. Isajevs S, Liepniece-Karele I, Janciauskas D, Moisejevs G, Putnins V, Funka K, et al. Gastritis staging: Interobserver agreement by applying OLGA and OLGIM systems. Virchows Arch. 2014;464(4):403–7.spa
dc.relation.references76. Rugge M, Meggio A, Pennelli G, Piscioli F, Giacomelli L, De Pretis G, et al. Gastritis staging in clinical practice: The OLGA staging system. Gut. 2007;56(5):631–6.spa
dc.relation.references77. Mera RM, Bravo LE, Constanza Camargo M, Bravo JC, Delgado AG, Romero-Gallo J, et al. Dynamics of Helicobacter pylori infection as a determinant of progression of gastric precancerous lesions: 16-year follow-up of an eradication trial. Gut. 2018;67(7):1239–46.spa
dc.relation.references78. Correa P. Clinical implications of recent developments in gastric cancer pathology and epidemiology. Semin Oncol. 1985;12(1):2–10.spa
dc.relation.references79. Lauren P. the Two Histological Main Types of Gastric Carcinoma: Diffuse and So-Called Intestinal-Type Carcinoma. an Attempt At a Histo-Clinical Classification. Acta Pathol Microbiol Scand. 1965;64:31–49.spa
dc.relation.references80. Kong YJ, Yi HG, Dai JC, Wei MX. Histological changes of gastric mucosa after Helicobacter pylori eradication: A systematic review and meta-analysis. World J Gastroenterol. 2014;20(19):5903–11.spa
dc.relation.references81. Chen HN, Wang Z, Li X, Zhou ZG. Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis. Gastric Cancer. 2016;19(1):166–75.spa
dc.relation.references82. Rokkas T, Rokka A, Portincasa P. A systematic review and meta-analysis of the role of Helicobacter pylori eradication in preventing gastric cancer. Ann Gastroenterol. 2017;30(4):414–23.spa
dc.relation.references83. Choi IJ, Kook M-C, Kim Y-I, Cho S-J, Lee JY, Kim CG, et al. Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer . N Engl J Med. 2018;378(12):1085–95.spa
dc.relation.references84. Wong BCY, Zhang L, Ma JL, Pan KF, Li JY, Shen L, et al. Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions. Gut. 2012;61(6):812–8.spa
dc.relation.references85. Huang XZ, Chen Y, Wu J, Zhang X, Wu CC, Zhang CY, et al. Aspirin and non-steroidal anti-inflammatory drugs use reduce gastric cancer risk: A dose-response meta-analysis. Oncotarget. 2017;8(3):4781–95.spa
dc.relation.references86. Hirasawa T, Gotoda T, Miyata S, Kato Y, Shimoda T, Taniguchi H, et al. Incidence of lymph node metastasis and the feasibility of endoscopic resection for undifferentiated-type early gastric cancer. Gastric Cancer. 2009;12(3):148–52.spa
dc.relation.references87. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.spa
dc.relation.references88. Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JWW. Recent trends of cancer in Europe: A combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer. 2008;44(10):1345–89.spa
dc.relation.references89. Correa P, Haenszel W, Cuello C, Tannenbaum S, Archer M. a Model for Gastric Cancer Epidemiology. Lancet. 1975;306(7924):58–60.spa
dc.relation.references90. Correa P. Gastric cancer: Two epidemics? Dig Dis Sci. 2011;56(5):1585–6.spa
dc.relation.references91. Pasechnikov V, Chukov S, Fedorov E, Kikuste I, Leja M. Gastric cancer: Prevention, screening and early diagnosis. World J Gastroenterol. 2014;20(38):13842–62.spa
dc.relation.references92. Shiotani A, Haruma K, Uedo N, Iishi H, Ishihara R, Tatsuta M, et al. Histological risk markers for non-cardia early gastric cancer: Pattern of mucin expression and gastric cancer. Virchows Arch. 2006;449(6):652–9.spa
dc.relation.references93. Lee JWJ, Zhu F, Srivastava S, Tsao SKK, Khor C, Ho KY, et al. Severity of gastric intestinal metaplasia predicts the risk of gastric cancer: a prospective multicentre cohort study (GCEP). Gut. 2022;71(5):854–63.spa
dc.relation.references94. Mansour-Ghanaei F, Joukar F, Yeganeh S, Sadeghi M, Daryakar A, Sepehrimanesh M. OLGA- and OLGIM-Based Staging in the Patients with Gastritis and Endoscopy Indications. Turkish J Gastroenterol. 2022;33(2):95–102.spa
dc.relation.references95. Wu M, Feng S, Qian M, Wang S, Zhang K. Helicobacter pylori Infection Combined with OLGA and OLGIM Staging Systems for Risk Assessment of Gastric Cancer: A Retrospective Study in Eastern China. Risk Manag Healthc Policy. 2022;15:2243–55.spa
dc.relation.references96. Carlosama YH, Acosta CP, Sierra CH, Rosero CY, Bolaños HJ. The Operative Link on Gastritis Assessment (OLGA) system as a marker for gastric cancer and dysplasia in a Colombian population at risk: A multicenter study. Biomedica. 2023;43:30–40.spa
dc.relation.references97. Zhou Y, Li HY, Zhang JJ, Chen XY, Ge ZZ, Li XB. Operative link on gastritis assessment stage is an appropriate predictor of early gastric cancer. World J Gastroenterol. 2016;22(13):3670–8.spa
dc.relation.references98. Chen M, Liu XL, Zhu XJ, Wu SR, Wang N, Li SB, et al. Endoscopic grading of gastric atrophy and histological gastritis staging on risk assessment for early gastric cancer: A case–control study. J Dig Dis. 2023;24(4):262–70.spa
dc.relation.references99. Piazuelo MB, Bravo LE, Mera RM, Camargo MC, Bravo JC, Delgado AG, et al. The Colombian Chemoprevention Trial: 20-Year Follow-Up of a Cohort of Patients With Gastric Precancerous Lesions. Gastroenterology. 2021;160(4):1106-1117.e3.spa
dc.relation.references100. Den Hollander WJ, Holster IL, Den Hoed CM, Capelle LG, Tang TJ, Anten MP, et al. Surveillance of premalignant gastric lesions: A multicentre prospective cohort study from low incidence regions. Gut. 2019;68(4):585–93.spa
dc.relation.references101. Kodama M, Murakami K, Okimoto T, Abe H, Sato R, Ogawa R, et al. Histological characteristics of gastric mucosa prior to Helicobacter pylori eradication may predict gastric cancer. Scand J Gastroenterol. 2013;48(11):1249–56.spa
dc.relation.references102. Tsai YC, Hsiao WH, Yang HB, Cheng HC, Chang WL, Lu CC, et al. The corpus-predominant gastritis index may serve as an early marker of helicobacter pylori-infected patients at risk of gastric cancer. Aliment Pharmacol Ther. 2013;37(10):969–78.spa
dc.relation.references103. Yun CY, Kim N, Lee J, Lee JY, Hwang YJ, Lee HS, et al. Usefulness of OLGA and OLGIM system not only for intestinal type but also for diffuse type of gastric cancer, and no interaction among the gastric cancer risk factors. Helicobacter. 2018;23(6):12–3.spa
dc.relation.references104. Rugge M, Genta RM, Fassan M, Valentini E, Coati I, Guzzinati S, et al. OLGA Gastritis Staging for the Prediction of Gastric Cancer Risk: A Long-term Follow-up Study of 7436 Patients. Am J Gastroenterol. 2018;113(11):1621–8.spa
dc.relation.references105. Huang Y, Chen J, Guo Y, Ding Z, Liang X, Zhang W, et al. Staging of operative link on gastritis assessment and operative link on gastric intestinal metaplasia systems for risk assessment of early gastric cancer: a case-control study. J Clin Pathol. 2023;12–3.spa
dc.relation.references106. Marcos P, Brito-Gonçalves G, Libânio D, Pita I, Castro R, Sá I, et al. Endoscopic grading of gastric intestinal metaplasia on risk assessment for early gastric neoplasia: Can we replace histology assessment also in the West? Gut. 2020;69(10):1762–8.spa
dc.relation.references107. Choi I, Cho S, Kook M, Kim C, Lee J. Validaton of gastritis OLGA-staging system for gastric cancer risk in a region of high prevalence: a case-control study. Helicobacter. 2012;17:76.spa
dc.relation.references108. Nieminen AA, Kontto J, Puolakkainen P, Virtamo J, Kokkola A. Comparison of operative link for gastritis assessment, operative link on gastric intestinal metaplasia assessment, and TAIM stagings among men with atrophic gastritis. World J Gastroenterol. 2020;26(24):3447–57.spa
dc.relation.references109. Satoh K, Osawa H, Yoshizawa M, Nakano H, Hirasawa T, Kihira K, et al. Assessment of atrophic gastritis using the OLGA system. Helicobacter. 2008;13(3):225–9.spa
dc.relation.references110. Chapelle N, Péron M, Quénéhervé L, Bourget A, Leroy M, Touchefeu Y, et al. Long-Term Follow-up of Gastric Precancerous Lesions in a Low GC Incidence Area. Clin Transl Gastroenterol. 2020;11(12):e00237.spa
dc.relation.references111. Esposito G, Dilaghi E, Cazzato M, Pilozzi E, Conti L, Carabotti M, et al. Endoscopic surveillance at 3 years after diagnosis, according to European guidelines, seems safe in patients with atrophic gastritis in a low-risk region. Dig Liver Dis. 2021;53(4):467–73.spa
dc.relation.references112. Latorre G, Silva F, Montero I, Bustamante M, Dukes E, Uribe J, et al. Comparison of OLGA and OLGIM as predictors of gastric cancer in a Latin American population: the ECHOS Study. Gut. 2024;73(10):e18.spa
dc.relation.references113. Kawamura M, Uedo N, Yao K, Koike T, Kanesaka T, Hatta W, et al. Endoscopic and histological risk stratification for gastric cancer using gastric intestinal metaplasia. J Gastroenterol Hepatol. 2024;1–2.spa
dc.relation.references114. Wang X, Han F, Wang C, Lyu B. The value of OLGA staging system in risk assessment of gastric precancerous states and precancerous lesions. Natl Med J China. 2022;102(12):853–7.spa
dc.relation.references115. Sun L, Jin X, Huang L, Zhao J, Jin H, Chen M, et al. Risk of progression in patients with chronic atrophic gastritis: A retrospective study. Front Oncol. 2022;12:1–2.spa
dc.relation.references116. Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. Published online August 8, 2022. doi:10.1136/gutjnl-2022-327745.spa
dc.relation.references117. Liou JM, Malfertheiner P, Smith SI, El-Omar EM, Wu MS. 40 years after the discovery of Helicobacter pylori: towards elimination of H pylori for gastric cancer prevention. Lancet. 2024;403(10444):2570–2.spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.licenseAtribución-NoComercial-SinDerivadas 4.0 Internacionalspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/spa
dc.subject.ddc610 - Medicina y salud::616 - Enfermedadesspa
dc.subject.ddc610 - Medicina y salud::615 - Farmacología y terapéuticaspa
dc.subject.decsNeoplasias Intestinalesspa
dc.subject.decsIntestinal Neoplasmseng
dc.subject.decsMetaanálisis como Asuntospa
dc.subject.decsMeta-Analysis as Topiceng
dc.subject.decsEnfermedades Genéticas Congénitasspa
dc.subject.decsGenetic Diseases, Inborneng
dc.subject.proposalNeoplasias Gástricasspa
dc.subject.proposalGastritis Atróficaspa
dc.subject.proposalMetaplasiaspa
dc.subject.proposalFactores de Riesgospa
dc.subject.proposalMetaanálisisspa
dc.subject.proposalRevisión Sistemáticaspa
dc.subject.proposalStomach Neoplasmseng
dc.subject.proposalGastritiseng
dc.subject.proposalAtrophiceng
dc.subject.proposalMetaplasiaeng
dc.subject.proposalRisk factorseng
dc.subject.proposalMeta-Analysiseng
dc.subject.proposalSystematic revieweng
dc.titleRiesgo de cáncer gástrico en pacientes con gastritis atrófica y metaplasia intestinal en estadios OLGA y OLGIM III y IV: revisión sistemática y metanálisisspa
dc.title.translatedGastric cancer risk in patients with atrophic gastritis and intestinal metaplasia in OLGA and OLGIM stages III and IV: systematic review and meta-analysiseng
dc.typeTrabajo de grado - Especialidad Médicaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_bdccspa
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aaspa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/masterThesisspa
dc.type.redcolhttp://purl.org/redcol/resource_type/TMspa
dc.type.versioninfo:eu-repo/semantics/acceptedVersionspa
dcterms.audience.professionaldevelopmentInvestigadoresspa
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2spa

Archivos

Bloque original

Mostrando 1 - 2 de 2
Miniatura
Nombre:
1019056346.2024.pdf
Tamaño:
959.56 KB
Formato:
Adobe Portable Document Format
Descripción:
Tesis de Especialidad en Gastroenterología
Descargar
Miniatura
Nombre:
Anexos.pdf
Tamaño:
123.03 KB
Formato:
Adobe Portable Document Format
Descripción:
Archivos anexos
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
5.74 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Especialidad en Gastroenterología